Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors

Journal of Molecular Modeling

Volumn 18, Issue 5, 2012, Pages 1791-1799

  Kumar, Hirdesh ^a   Shah, Anup ^a   Sobhia, M Elizabeth ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

ALR2; Detoxification; Docking; Induced fit cavity; Selectivity; Specificity

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; FIDARESTAT; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE; METHYLGLYOXAL; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; POLYOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SORBITOL; ZOPOLRESTAT;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DETOXIFICATION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG DESIGN; DRUG METABOLISM; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HUMAN; HYPERGLYCEMIA; METABOLITE; MICROVASCULATURE; MOLECULAR DOCKING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ALDEHYDE REDUCTASE; BENZOTHIAZOLES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DATABASES, PROTEIN; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; NADP; PHTHALAZINES; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY;

EID: 84861230090     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-011-1195-0     Document Type: Article

References (36)

1. Stratton IM, Adler AI, Neil HW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412 (Pubitemid 30609442)
2. Gonzalez RG, Barnett P, Aguayo J, Cheng HM, Chylack LT (1984) Direct measurement of polyol pathway activity in the ocular lens. Diabetes 33:196-199 (Pubitemid 14184708)
3. Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA (1983) Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes 32:988-992 (Pubitemid 14225114)
4. Ramana KV, Willis MS, White MD, Horton JW, DiMaio JM, Srivastava D, Bhatnagar A, Srivastava SK (2006) Endotoxininduced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 114:1838-1846 (Pubitemid 44673359)
5. Regenold WT, Kling MA, Hauser P (2000) Elevated sorbitol concentration in the cerebrospinal fluid of patients with mood disorders. Psychoneuroendocrinology 25:593-606 (Pubitemid 30407311)
6. Hasuike Y, Nakanishi T, Otaki Y, Nanami M, Tanimoto T, Taniguchi N, Takamitsu Y (2002) Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am J Kidney Dis 40:464-471 (Pubitemid 34971273)
7. Meyer WR, Doyle MB, Grifo JA, Lipetz KJ, Oates PJ, DeCherney AH, Diamond MP (1992) Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague- Dawley rat. Am J Obstet Gynecol 167:1837-1843 (Pubitemid 23009333)
8. Lee KWY, Ko BCB, Jiang Z, Cao D, Chung SSM (2001) Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 12:129-132 (Pubitemid 32207361)
9. Luo Y, Zhang J, Liu Y, Shaw AC, Wang X, Wu S, Zeng X, Chen J, Gao Y, Zheng D (2005) Comparative proteome analysis of breast cancer and normal breast. Mol Biotechnol 29:233-244 (Pubitemid 41411176)
10. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Michael J (2003) Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Birrer Clin Cancer Res AACR 9:4811-4818 (Pubitemid 37323284)
11. Yim EK, Lee KH, Kim CJ, Park JS (2006) Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells. Int J Gynecol Cancer 16:690
12. SaraswatM,Mrudula T,Kumar PU, Suneetha A, Rao TS, Srinivasulu M, Reddy GB (2006) Overexpression of aldose reductase in human cancer tissues. Med Sci Monit 12:CR525-CR529 (Pubitemid 44916060)
13. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ (2009) Aldose reductase enzyme and its implication to major health problems of the 21 (st) Century. Curr Med Chem 16:734-752
14. Jez JM, Penning TM (2001) The aldo-keto reductase (AKR) superfamily: an update. Chem Biol Interact 130:499-525 (Pubitemid 32295840)
15. Wermuth B, Burgisser H, Bohren K, Eur WJP (1982) Purification and characterization of human-brain aldose reductase. J Biochem 127:279-284 (Pubitemid 13206474)
16. Ris MM, Wartburg JP (1973) Heterogeneity of NADPHdependent aldehyde reductase from human and rat brain. Eur J Biochem 37:69-77
17. Bohren KM, Bullock B, Wermuth B, Gabbay KH (1989) The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem 264:9547-9551
18. El-Kabbani O, Carbone V, Darmanin C, Oka M, Mitschler A, Podjarny A, Schulze-Briese C, PtC R (2005) Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. J Med Chem 48:5536-5542 (Pubitemid 41209251)
19. Gallego O, Ruiz F, Ardèvo A, Domínguez M, Alvarez R, de Lera A, Rovira C, Farrés J, Parés X (2007) Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci 104:20764-20769
20. Sheetz MJ, King GL (2002) Molecular understanding of hyperglycemia's adverse effects for diabetic complications. Am Med Assoc 288:2579-2588 (Pubitemid 35386893)
21. Wilson DK, Bohren KM, Gabbay KH, Quiocho FA (1992) An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science 257:81-84
22. Rondeau JM, Tete-Favier F, Podjarny A, Reymann JM, Barth P, Biellmann JF, Moras D (1992) Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. 30:469-472
23. Srivastava S, Dixit BL, Cai J, Sharma S, Hurst HE, Bhatnagar A, Srivastava SK (2000) Metabolism of lipid peroxidation product, 4-hydroxynonenal (HNE) in rat erythrocytes: role of aldose reductase. Free Radical Biol Med 29:642-651
24. Tarle I, Borhani DW, Wilson DK, Quiocho FA, Petrash JM (1993) Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110. J Biol Chem 268:25687-25693 (Pubitemid 23358181)
25. Costantino L, Rastelli G, Vescovini K, Cignarella G, Vianello P, Del Corso A, Cappiello M, Mura U, Barlocco D (1996) Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. J Med Chem 39:4396-4405 (Pubitemid 26359396)
26. Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27
27. Sato Y, Nakaya A, Shiraishi K, Kawashima S, Goto S, Kanehisa M (2001) Genome Informatics Series 230-231
28. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ (1998) Multiple sequence alignment with Clustal X. Trends Biochem Sci 23:403-405 (Pubitemid 28511382)
29. Rabiner L, Juang B (1986) An introduction to hidden Markov models. IEEE ASSP Mag 3:4-16
30. Eddy SR (1998) Profile hidden Markov models. Bioinformatics 14:755-763 (Pubitemid 28552108)
31. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S (2002) The protein data bank. Acta Crystallogr D Biol Crystallogr 58:899-907 (Pubitemid 34653017)
32. -(2005) SYBYL Molecular Modeling Package. Tripos Inc, St. Louis, M.O.
33. Laurie ATR, Jackson RM (2005) Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 21:1908-1916 (Pubitemid 40668026)
34. GLIDE, version 5.0, Schrödinger Inc, San Diego, CA, USA
35. QikProp, version 3.1,Schrödinger Inc, San Diego, CA, USA
36. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647-671 (Pubitemid 46023928)